All News
DSB: Managing Methotrexate Toxicity (Best of 2015: #1)
Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA.
Read ArticleHow I Choose Biologics (Best of 2015)
Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.
Read ArticleAlcohol and Methotrexate - What Do You Advise? (Best of 2015: #9)
What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?
Read ArticleRA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news
Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.
Read ArticleEULAR 2015 Psoriatic Arthritis Treatment Guidelines
The management of psoriatic disease, including psoriatic arthritis (PsA) has evolved significantly in the last decade. Nevertheless, there are still some uncertainties - such as what the role of methotrexate should be, and when to use newer and novel therapies.
Read ArticleThe Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read ArticleInterstitial Lung Disease Not Increased with Biologics
Extraarticular manifestations affect more then half of rheumatoid arthritis (RA) patients, and interstitial lung disease or "RA lung" is one of the more prevalent. The frequency of ILD in patients with RA varies from 5% to 58%.
Read ArticleFrom Psoriasis to PsA: Who and Why?
The number of patients with psoriasis who go on to develop psoriatic arthritis (PsA) is considerably higher than has previously been estimated, a prospective cohort study found.
Read ArticlePsoriasis May Not Be a Risk for CV Events
Patients with psoriatic skin and joint disease are uniquely susceptible to multiple comorbidities, obesity and possibly more cardiovascular risks. In rheumatoid arthritis, the increased CV risk and CV events have been closely aligned with inflammation and disease activity.
Read ArticleSB4 - A Second Biosimilar Up For Review in Europe
A biosimilar of etanercept (Enbrel) made by the South Korean company Samsung Bioepis is under consideration by regulators in the European Union. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim with its version of etanercept.
Read ArticleAlcohol and Methotrexate - What Do You Advise?
What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?
Read ArticleAre Guidelines Worth the Cost?
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
Hypertension Increased in Psoriasis Treated with NSAIDs, Cyclosporine or Steroids
Psoriasis and psoriatic arthritis patient have significantly higher rates of comorbidity, including hypertension (HTN). This population-based, nested case–control study analyzed an inception psoriasis cohort from Taiwan's National Health Insurance Research Database between 2000–2010.
Read ArticleBiology of Bone Remodeling in Psoriatic Disease
Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.
Read ArticleBiosimilars and the FDA
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
Read ArticleRepeat Skin Cancer Risk with Methotrexate and Biologics
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Read ArticleHigh Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read ArticleVertebral Fractures in 10% of Spondyloarthritis Patients
Vertebral fractures are not uncommon in patients with ankylosing spondylitis and spondyloarthritis.
Read ArticleWeight Loss Improves Skin Outcomes in Psoriasis
A recent presentation at the European Academy of Dermatology and Venereology (EADV) meeting in Copenhagen showed the long-term outcomes of weight loss in psoriasis.
Read Article